<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.10.17.21265100</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Intensive Care and Critical Care Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intravenous corticosteroid treatment in adult patients with sepsis defined by the Sepsis-3 criteria: a systematic review and meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7102-8604</contrib-id>
<name><surname>Wu</surname><given-names>Yu-Pu</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lin</surname><given-names>Cheng-Kuan</given-names></name>
<degrees>MD, ScD</degrees>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hamaya</surname><given-names>Rikuta</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>Fei-Yang</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chien</surname><given-names>Yung-Shin</given-names></name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hsu</surname><given-names>Yu-Tien</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Szu-Ta</given-names></name>
<degrees>MD, PhD, MPH</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Papatheodorou</surname><given-names>Stefania</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Epidemiology, Harvard T.H. Chan School of Public Health</institution>, Boston, MA, <country>U.S.A.</country></aff>
<aff id="a2"><label>2</label><institution>Department of Environmental Health, Harvard T.H. Chan School of Public Health</institution>, Boston, MA, <country>U.S.A.</country></aff>
<aff id="a3"><label>3</label><institution>School of Arts and Sciences, Massachusetts College of Pharmacy and Health Sciences</institution>, MA, <country>U.S.A.</country></aff>
<aff id="a4"><label>4</label><institution>Department of Physiology, Development and Neuroscience, University of Cambridge</institution>, <country>United Kingdom</country></aff>
<aff id="a5"><label>5</label><institution>Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health</institution>, Boston, MA, <country>U.S.A.</country></aff>
<aff id="a6"><label>6</label><institution>Population Health Sciences, Graduate School of Arts and Sciences, Harvard University</institution>, <country>U.S.A.</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label><bold>Corresponding author:</bold> Yu-Pu Wu, <email>yupuwu@hsph.harvard.edu</email>; <email>hiarpu@gmail.com</email>, Mail address: 677 Huntington Ave., Boston, MA 02115, Phone: &#x002B;1 857-205-2678</corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.10.17.21265100</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>10</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>17</day>
<month>10</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21265100.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Objectives</title>
<p>To summarize the effects of intravenous corticosteroid treatment for sepsis defined by the Sepsis-3 criteria in adult patients.</p>
</sec>
<sec>
<title>Design</title>
<p>Systematic review and meta-analysis.</p>
</sec>
<sec>
<title>Methods</title>
<p>We searched RCTs from PubMed, Embase, <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, Cochrane Central Register of Controlled Trials, Web of Science, and International Clinical Trials Registry Platform from inception to July 12th, 2019 and updated on June 28th, 2020. Conference proceedings from relevant societies and the reference lists of previous reviews were manually screened. Abstract or full-text articles were screened by two independent investigators. We included RCTs where (1) the participants had infections and the baseline Sequential Organ Failure Assessment (SOFA) score &#x2265; 2 (the Sepsis-3 definitions) (2) the intervention involved any intravenous corticosteroids; (3) the control group received placebo or standard of care (4) the outcomes of interest included mortality or clinical recovery. We chose the 28-day mortality as the pre-specified primary outcome and risk ratio (RR) as the effect measure. We followed PRISMA guidelines and chose random-effects models for the pooled analyses.</p>
</sec>
<sec>
<title>Results</title>
<p>This study included 24 RCTs and 19 of them (7,115 participants) reported the 28-day mortality. Pooled analyses showed that intravenous corticosteroid treatment compared to placebo or standard of care was not associated with a lower risk of 28-day mortality (RR, 0.88; 95&#x0025;CI, 0.73 to 1.05), but with a higher risk of hyperglycemia (RR, 1.16; 95&#x0025;CI, 1.06 to 1.27). Sensitivity analysis of high-quality studies revealed a similar result for the 28-day mortality (RR, 0.95; 95&#x0025;CI, 0.86 to 1.05).</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Our findings suggested that intravenous corticosteroids compared to placebo or standard of care may not reduce the 28-day mortality in adult patients with sepsis defined by the Sepsis-3 criteria. Further studies are warranted to clarify the roles of disease severity and treatment timing in the effects of corticosteroid treatment in this population.</p>
</sec>
<sec>
<title>PROSPERO registration number</title>
<p>CRD42019143083</p>
</sec>
<sec>
<title>Strengths and limitations of this study</title>
<list list-type="bullet">
<list-item><p>This is the first systematic review and meta-analysis that summarized the effects of intravenous corticosteroid treatments in patients with sepsis defined by the Sepsis-3 criteria.</p></list-item>
<list-item><p>We provide the quality of evidence to support the development of treatment guidelines specific to the Sepsis-3 cohort.</p></list-item>
<list-item><p>We only include randomized controlled trials in this systematic review and meta-analysis, which exclude less controlled evidences from clinical settings closer to our daily practice.</p></list-item>
<list-item><p>The Sepsis-3 definitions will be retrospectively applied to the included studies, so clinical trials without enough reported baseline data available may be excluded.</p></list-item>
</list>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Sepsis</kwd>
<kwd>Shock</kwd>
<kwd>Septic</kwd>
<kwd>Survival</kwd>
<kwd>Glucocorticoids</kwd>
<kwd>Mortality</kwd>
</kwd-group>
<counts>
<page-count count="34"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>Yu-Pu Wu, Cheng-Kuan Lin, Fei-Yang Huang, Yung-Shin Chien, Yu-Tien Hsu, Szu-Ta Chen, and Stefania Papatheodorou declared that they had no conflict of interest with respect to the financial interests, activities, relationships, and affiliations. The activity of Rikuta Hamaya was supported by The Nakajima Foundation.</p></notes>
<notes notes-type="clinical-protocols-statement">
<title>Clinical Protocols</title><p>
<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=143083">https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=143083</ext-link>
</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This study did not receive any funding
</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>N/A</p><p>I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Controversy over the use of intravenous corticosteroid in patients with sepsis or septic shock remained unsettled for decades.<sup><xref rid="c1" ref-type="bibr">1</xref></sup> Published randomized controlled trials (RCTs) reported inconsistent findings.<sup><xref rid="c1" ref-type="bibr">1</xref></sup> In particular, the two largest RCTs, the APROCCHSS trial<sup><xref rid="c2" ref-type="bibr">2</xref></sup> and the ADRENAL trial,<sup><xref rid="c3" ref-type="bibr">3</xref></sup> published in 2018 did not agree with each other. The APROCCHSS trial suggested that corticosteroid use was associated with reduced 90-day mortality,<sup><xref rid="c2" ref-type="bibr">2</xref></sup> whereas the ADRENAL trial did not.<sup><xref rid="c3" ref-type="bibr">3</xref></sup> An explanation for this inconsistency could be different inclusion criteria for patients with septic shock between these two studies. The ADRENAL trial<sup><xref rid="c3" ref-type="bibr">3</xref></sup> defined the study cohort using an earlier definition for sepsis,<sup><xref rid="c4" ref-type="bibr">4</xref></sup> the systematic inflammatory response syndrome (SIRS) following infection. Instead, the APROCCHSS trial enrolled participants based on the Sequential Organ Failure Assessment (SOFA) score.<sup><xref rid="c2" ref-type="bibr">2</xref></sup> As a result, the APROCCHSS trial had a higher mortality rate in the control group compared to that in the ADRENAL trial (49.1&#x0025; vs 28.8&#x0025;).<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c3" ref-type="bibr">3</xref></sup> Additional inconsistencies of the inclusion criteria also existed among other RCTs. For example, some trials enrolled patients with concomitant use of vasopressor agents,<sup><xref rid="c5" ref-type="bibr">5</xref>-<xref rid="c7" ref-type="bibr">7</xref></sup> whereas others did not.<sup><xref rid="c8" ref-type="bibr">8</xref>-<xref rid="c10" ref-type="bibr">10</xref></sup> Due to inconsistent definitions of patients with sepsis, the results are difficult to summarize to inform clinical practice.</p>
<p>In 2016, a new consensus definition for the diagnosis of sepsis, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), was proposed based on the SOFA score to standardize and operationalize the diagnostic criteria for sepsis and septic shock.<sup><xref rid="c11" ref-type="bibr">11</xref></sup> The use of the SOFA score not only remedied the high false positive rate of the SIRS definition in identifying patients with sepsis,<sup><xref rid="c12" ref-type="bibr">12</xref></sup> but was validated as a better predictor for mortality.<sup><xref rid="c11" ref-type="bibr">11</xref></sup> Thus, the Sepsis-3 definitions were increasingly adopted by researchers and clinicians to ensure consistency in clinical studies and daily practice.<sup><xref rid="c11" ref-type="bibr">11</xref> <xref rid="c13" ref-type="bibr">13</xref>-<xref rid="c15" ref-type="bibr">15</xref></sup></p>
<p>After the Sepsis-3 definitions were proposed, to the best of our knowledge, only one post-hoc analysis of the ADRENAL trial has applied the Sepsis-3 criteria for septic shock,<sup><xref rid="c16" ref-type="bibr">16</xref></sup> but the association between intravenous corticosteroids and mortality in patients with sepsis defined by the Sepsis-3 criteria has not yet been summarized. Thus, we aimed to conduct this systematic review and meta-analysis to summarize the efficacy of corticosteroids in patients with sepsis defined by the Sepsis-3 criteria.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<p>This systematic review and meta-analysis was conducted based on a pre-specified protocol registered in the International prospective register of systematic reviews (PROSPERO) on October 24<sup>th</sup>, 2019 (registered number: CRD42019143083). We followed the PRISMA reporting guideline<sup><xref rid="c17" ref-type="bibr">17</xref></sup> to report our study design and findings.</p>
<sec id="s2a">
<title>Search strategy</title>
<p>We searched published or completed RCTs on the efficacy of corticosteroids in adult patients with sepsis by using the searching terms: (1) corticosteroids; (2) infectious diseases or syndromes associated with sepsis; and (3) randomized controlled trials and their synonyms. The searching included multiple databases (i.e. PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, and International Clinical Trials Registry Platform) as well as online resources of leading societies for intensive care, such as Society of Critical Care Medicine, International Sepsis Forum, European Society of Intensive Care Medicine, American Thoracic Society, and World Federation of Societies of Intensive and Critical Care. All the above-mentioned sources were searched from the inception till July 12, 2019 and updated on June 28th, 2020. Reference lists of the previous relevant review articles<sup><xref rid="c18" ref-type="bibr">18</xref>-<xref rid="c20" ref-type="bibr">20</xref></sup> were further screened manually. The detailed search strategy was reported in eTable 1 (see online supplementary materials).</p>
</sec>
<sec id="s2b">
<title>Eligibility criteria</title>
<p>PICOS statement (Patients/ Intervention/ Comparison/ Outcome/ Study design) were set up <italic>a priori</italic> as below: (1) Adult patients (age &#x2265;18 years) that had infections and baseline SOFA score &#x003E;2, as defined by the Sepsis-3 criteria for sepsis. The baseline SOFA score was either directly reported in the trials, or indirectly derived from the baseline biochemical laboratory data and the inclusion criteria of the trials. If the baseline SOFA score was reported, we included the trials when approximately 97.5&#x0025; of subjects fulfilled the Sepsis-3 criteria for sepsis, indicated by the approximation that the mean of baseline SOFA score minus twice of the standard deviation (SD) was equal or larger than 2. If the median with interquartile range (IQR) was reported, we approximated the mean with the median, and assumed the IQR to be 1.35 SD. The SOFA scores were calculated based on the Sepsis-3 criteria<sup><xref rid="c11" ref-type="bibr">11</xref></sup>; (2) Interventions included any intravenous corticosteroids. (3) Comparison group received either placebo or standard of care, such as antibiotics, intravenous fluid support, mechanical ventilation, and vasopressors. (4) Studies reported at least one of the following pre-specified outcomes were eligible: 28-day mortality (our primary outcome of interest), 90-day mortality, length of intensive care unit (ICU) stay, length of hospital stay, SOFA score on day 7, in-hospital mortality, ICU mortality, and adverse events including hyperglycemia, gastrointestinal bleeding, superinfection, and the total numbers of any adverse events; (5) We limited our search in randomized controlled trials. Therefore, studies in which the treatments were not randomly assigned were excluded.</p>
<p>To focus on the efficacy of corticosteroids, we excluded trials in which both the experimental group and the control group received corticosteroid treatment. Notably, abstract-only studies that fulfilled our PICOS statement were still eligible for our study. No language restriction was applied.</p>
</sec>
<sec id="s2c">
<title>Study selection</title>
<p>Each article was independently screened, assessed and selected by at least two authors (Y.W., C.L., F.H., Y.C., Y.H., S.C.). In case of disagreements, consensus was reached through discussion among the investigators or after consultation with a third reviewer (S.P.).</p>
</sec>
<sec id="s2d">
<title>Data extraction</title>
<p>Four independent reviewers (Y.W., R.H., F.H., Y.C.) extracted relevant information from the included trials. Specifically, we extracted data including general characteristics of the articles (e.g. authors, years of publication, sample sizes), information related to the baseline SOFA scores (e.g. the inclusion criteria or the biochemical laboratory data), and information of the treatment (types of medications, dosages, and treatment durations), and all outcomes of interest. All disagreements were resolved through the discussion among reviewers. Missing or unpublished data were obtained by consulting previous related review articles.<sup><xref rid="c18" ref-type="bibr">18</xref> <xref rid="c19" ref-type="bibr">19</xref></sup></p>
</sec>
<sec id="s2e">
<title>Risk of bias and quality of evidence</title>
<p>Two reviewers (Y.W. and R.H.) independently assessed the risk of bias for each included trial using the revised Cochrane risk-of-bias tool, RoB2.<sup><xref rid="c21" ref-type="bibr">21</xref></sup> The same reviewers also independently adopted the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to evaluate the quality of evidence for each outcome of interest.<sup><xref rid="c22" ref-type="bibr">22</xref></sup> The third reviewer (S.P.) was consulted in case of disagreements.</p>
<p>Specifically, there were five domains in the RoB2, including the randomization process, deviations from the intended interventions, the missing outcome data, the measurement of the outcome, and the selection of the reported results. Each domain was judged as &#x2018;low&#x2019; or &#x2018;high&#x2019; risk of bias, or with &#x2018;some concerns&#x2019;. An overall risk of bias was reported for each trial, and a trial was considered having some concerns or high-risk for overall bias if judged as &#x2018;some concerns&#x2019; or &#x2018;high&#x2019; risk of bias in any of the five domains, respectively. As recommended by the GRADE system, the quality of evidence for each outcome of interest was evaluated based on the risk of bias,<sup><xref rid="c23" ref-type="bibr">23</xref></sup> imprecision,<sup><xref rid="c24" ref-type="bibr">24</xref></sup> inconsistency,<sup><xref rid="c25" ref-type="bibr">25</xref></sup> indirectness,<sup><xref rid="c26" ref-type="bibr">26</xref></sup> and the reporting bias.<sup><xref rid="c27" ref-type="bibr">27</xref></sup> An overall quality of evidence for each outcome was rated as high, moderate, low, or very low.</p>
</sec>
<sec id="s2f">
<title>Data synthesis</title>
<p>We conducted pooled analyses for all the outcomes of interest using random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) method which outperformed the DerSimonian-Laird method particularly in having lower type-I error rates when sample sizes varied across trials.<sup><xref rid="c28" ref-type="bibr">28</xref></sup> Risk ratio (RR) of dichotomous outcomes and risk difference (RD) of continuous outcomes were reported with 95&#x0025; confidence intervals (95&#x0025; CI) using Mantel-Haenszel method and inverse variance method, respectively. Statistical significance level was defined as a two-tailed P-value &#x003C;0.05. We used Chi-square test and I<sup>2</sup> statistics to evaluate the magnitude of the heterogeneity for each outcome. Significance level of the Chi-square test was defined as a two-tailed P-value &#x003C;0.1. As defined by the Cochrane Handbook,<sup><xref rid="c29" ref-type="bibr">29</xref></sup> moderate or substantial heterogeneity was considered if I<sup>2</sup> statistics &#x2265;30&#x0025; or &#x2265;50&#x0025;, respectively. The reporting bias for each outcome was visually evaluated based on the funnel plot. If at least 10 trials were pooled, the Egger test for the continuous outcomes or the Harbord test for the dichotomized outcomes were used to test the asymmetry of the funnel plot with the significance level of 0.1.<sup><xref rid="c29" ref-type="bibr">29</xref> <xref rid="c30" ref-type="bibr">30</xref></sup></p>
</sec>
<sec id="s2g">
<title>Subgroup analysis</title>
<p>We performed pre-specified subgroup analyses based on the duration of corticosteroid treatments (&#x2264;7 days vs &#x003E;7 days), average daily hydrocortisone equivalent dose (&#x2264;200mg vs &#x003E;200mg), severity of sepsis (sepsis vs septic shock based on the Sepsis-3 definitions), and types of the corticosteroids (hydrocortisone, methylprednisolone, hydrocortisone plus fludrocortisone, betamethasone, or dexamethasone). A mixed-effects model<sup><xref rid="c31" ref-type="bibr">31</xref></sup> was used for the subgroup comparisons with a significance level of 0.05.</p>
</sec>
<sec id="s2h">
<title>Sensitivity analysis</title>
<p>We performed the sensitivity analyses by (1) excluding trials with &#x003C; 100 total patients; (2) excluding studies with &#x003C;10 events in either the experimental group or the control group; (3) excluding studies with some concerns or high risk of overall bias; (4) excluding studies without a double-blind design; (5) excluding studies published before 2012 because an updated international guideline for the treatment of sepsis and septic shock was published in 2012<sup><xref rid="c32" ref-type="bibr">32</xref></sup>; (6) using a random-effects model with DerSimonian-Laird method; and (7) using a fix-effects model.</p>
<p>R (version 3.6.1) and packages meta, robvis, and dmetar<sup><xref rid="c33" ref-type="bibr">33</xref></sup> were used for all the analyses.</p>
</sec>
<sec id="s2i">
<title>Patient and public involvement</title>
<p>This systematic review and meta-analysis did not have direct patients or public involvement.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<p>Of the total 21,143 screened articles, 24 RCTs<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c3" ref-type="bibr">3</xref> <xref rid="c5" ref-type="bibr">5</xref>-<xref rid="c10" ref-type="bibr">10</xref> <xref rid="c34" ref-type="bibr">34</xref>-<xref rid="c49" ref-type="bibr">49</xref></sup> fulfilled our inclusion criteria and were included for meta-analysis (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Evidence that the included subjects fulfilled the Sepsis-3 criteria (baseline SOFA score&#x2265;2) were reported in <xref rid="tbl1" ref-type="table">Table 1</xref>. Of the 24 included trials, 1 trial enrolled participants based on the Sepsis-3 criteria<sup><xref rid="c49" ref-type="bibr">49</xref></sup>; and 9 trials<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c5" ref-type="bibr">5</xref> <xref rid="c8" ref-type="bibr">8</xref>-<xref rid="c10" ref-type="bibr">10</xref> <xref rid="c34" ref-type="bibr">34</xref> <xref rid="c37" ref-type="bibr">37</xref> <xref rid="c38" ref-type="bibr">38</xref> <xref rid="c40" ref-type="bibr">40</xref></sup> directly reported the patients&#x2019; baseline SOFA scores. We indirectly estimated the baseline SOFA scores for the other 14 studies<sup><xref rid="c3" ref-type="bibr">3</xref> <xref rid="c6" ref-type="bibr">6</xref> <xref rid="c7" ref-type="bibr">7</xref> <xref rid="c35" ref-type="bibr">35</xref> <xref rid="c36" ref-type="bibr">36</xref> <xref rid="c39" ref-type="bibr">39</xref> <xref rid="c41" ref-type="bibr">41</xref>-<xref rid="c48" ref-type="bibr">48</xref></sup> based on the reported biochemical laboratory data or the inclusion criteria of these trials. Notably, 2 RCTs<sup><xref rid="c45" ref-type="bibr">45</xref> <xref rid="c48" ref-type="bibr">48</xref></sup> were evaluated only by the abstracts due to the inaccessibility of the main texts. For the treatment group, hydrocortisone,<sup><xref rid="c3" ref-type="bibr">3</xref> <xref rid="c6" ref-type="bibr">6</xref> <xref rid="c8" ref-type="bibr">8</xref>-<xref rid="c10" ref-type="bibr">10</xref> <xref rid="c34" ref-type="bibr">34</xref> <xref rid="c36" ref-type="bibr">36</xref>-<xref rid="c41" ref-type="bibr">41</xref> <xref rid="c43" ref-type="bibr">43</xref> <xref rid="c45" ref-type="bibr">45</xref>-<xref rid="c47" ref-type="bibr">47</xref></sup> methylprednisolone,<sup><xref rid="c35" ref-type="bibr">35</xref> <xref rid="c44" ref-type="bibr">44</xref></sup> hydrocortisone plus fludrocortisone,<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c7" ref-type="bibr">7</xref></sup> and dexamethasone<sup><xref rid="c5" ref-type="bibr">5</xref></sup> were used in 16, 2, 2, and 1 trials, respectively. Two other studies used the combination of hydrocortisone, Vitamin C, and thiamine,<sup><xref rid="c48" ref-type="bibr">48</xref> <xref rid="c49" ref-type="bibr">49</xref></sup> and the other trial administered either dexamethasone or methylprednisolone to the participants in the treatment group.<sup><xref rid="c42" ref-type="bibr">42</xref></sup> For the control group, 20 RCTs<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c3" ref-type="bibr">3</xref> <xref rid="c5" ref-type="bibr">5</xref>-<xref rid="c10" ref-type="bibr">10</xref> <xref rid="c34" ref-type="bibr">34</xref>-<xref rid="c40" ref-type="bibr">40</xref> <xref rid="c42" ref-type="bibr">42</xref> <xref rid="c43" ref-type="bibr">43</xref> <xref rid="c45" ref-type="bibr">45</xref>-<xref rid="c47" ref-type="bibr">47</xref></sup> compared corticosteroid use with placebo, whereas 4 studies<sup><xref rid="c41" ref-type="bibr">41</xref> <xref rid="c44" ref-type="bibr">44</xref> <xref rid="c48" ref-type="bibr">48</xref> <xref rid="c49" ref-type="bibr">49</xref></sup> provided standard of care for the patients in the control group.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>Characteristics of the 24 Included Trials</p></caption>
<graphic xlink:href="21265100v1_tbl1.tif"/>
<graphic xlink:href="21265100v1_tbl1a.tif"/>
</table-wrap>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><p>Study Selection Process with Reasons for Exclusion</p></caption>
<graphic xlink:href="21265100v1_fig1.tif"/>
</fig>
<sec id="s3a">
<title>Risk of bias and quality of evidence</title>
<p>eFigure 1 and 2 (see online supplementary materials) displays the risk of bias for each domain. Of the 24 trials, 6 trials<sup><xref rid="c3" ref-type="bibr">3</xref> <xref rid="c6" ref-type="bibr">6</xref> <xref rid="c7" ref-type="bibr">7</xref> <xref rid="c9" ref-type="bibr">9</xref> <xref rid="c37" ref-type="bibr">37</xref> <xref rid="c47" ref-type="bibr">47</xref></sup> were considered having low risk of bias across all 5 domains, 8 studies<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c5" ref-type="bibr">5</xref> <xref rid="c8" ref-type="bibr">8</xref> <xref rid="c34" ref-type="bibr">34</xref> <xref rid="c36" ref-type="bibr">36</xref> <xref rid="c40" ref-type="bibr">40</xref> <xref rid="c44" ref-type="bibr">44</xref> <xref rid="c45" ref-type="bibr">45</xref></sup> had some concerns, and 10 studies<sup><xref rid="c10" ref-type="bibr">10</xref> <xref rid="c35" ref-type="bibr">35</xref> <xref rid="c38" ref-type="bibr">38</xref> <xref rid="c39" ref-type="bibr">39</xref> <xref rid="c41" ref-type="bibr">41</xref>-<xref rid="c43" ref-type="bibr">43</xref> <xref rid="c46" ref-type="bibr">46</xref> <xref rid="c48" ref-type="bibr">48</xref> <xref rid="c49" ref-type="bibr">49</xref></sup> had overall high risk of bias. Trials with overall high risk of bias were mostly due to non-double blinded designs<sup><xref rid="c42" ref-type="bibr">42</xref>-<xref rid="c44" ref-type="bibr">44</xref> <xref rid="c48" ref-type="bibr">48</xref> <xref rid="c49" ref-type="bibr">49</xref></sup> or premature termination.<sup><xref rid="c38" ref-type="bibr">38</xref> <xref rid="c39" ref-type="bibr">39</xref></sup></p>
<p>eTable 2 (see online supplementary materials) details the judgement for the risk of bias. The GRADE assessment for each outcome is shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. An overall quality of evidence for the 28-day mortality was high, and most secondary outcomes had medium-to-high quality.</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption><p>Summary of Findings with Quality of Evidence</p></caption>
<graphic xlink:href="21265100v1_tbl2.tif"/>
</table-wrap>
</sec>
<sec id="s3b">
<title>Primary outcome</title>
<p>Nineteen trials<sup><xref rid="c2" ref-type="bibr">2</xref> <xref rid="c3" ref-type="bibr">3</xref> <xref rid="c5" ref-type="bibr">5</xref>-<xref rid="c10" ref-type="bibr">10</xref> <xref rid="c36" ref-type="bibr">36</xref>-<xref rid="c40" ref-type="bibr">40</xref> <xref rid="c42" ref-type="bibr">42</xref>-<xref rid="c45" ref-type="bibr">45</xref> <xref rid="c47" ref-type="bibr">47</xref> <xref rid="c48" ref-type="bibr">48</xref></sup> reported the risks of 28-day mortality in which 3,564 out of 7,115 participants (50.1&#x0025;) received corticosteroid treatments. The summarized risk of 28-day mortality in patients with sepsis was not lower after corticosteroid treatment compared to the control group with placebo or standard of care (<xref rid="fig2" ref-type="fig">Figure 2</xref>: RR, 0.88; 95&#x0025; CI, 0.73 to 1.05; P=0.15; I<sup>2</sup> = 20&#x0025;). No obvious asymmetry was found by visual inspections of the funnel plot (eFigure 3 in the online supplementary materials). The Harbord test also supported the absence of reporting bias (P=0.11). All the sensitivity analyses except the results from the fix-effects model were consistent with the primary analysis (<xref rid="tbl3" ref-type="table">Table 3</xref> and eFigure 4-10 in the online supplementary materials). The sensitivity analysis based on 6 trials with low risk of overall bias agreed with the primary analysis (eFigure 6 in the online supplementary materials: RR, 0.95; 95&#x0025; CI, 0.86 to 1.05).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><p>Forest Plot of the Pooled Effect of Corticosteroids Compared to Placebo or Standard of Care on 28-day Mortality in Patients with Sepsis Defined by the Sepsis-3 Criteria</p>
<p>Abbreviation: RR, Risk Ratio;</p>
<p>We used the random-effects model with Mantel-Haenszel method to estimate the risk ratios;</p>
<p>Size of blue squares, weight of each trial; horizontal lines, 95&#x0025; CIs; diamond, the overall risk ratio with 95&#x0025; CI.</p></caption>
<graphic xlink:href="21265100v1_fig2.tif"/>
</fig>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3.</label>
<caption><p>Subgroup and Sensitivity Analyses</p></caption>
<graphic xlink:href="21265100v1_tbl3.tif"/>
</table-wrap>
</sec>
<sec id="s3c">
<title>Secondary outcomes and adverse events</title>
<p><xref rid="tbl2" ref-type="table">Table 2</xref> and eFigure 11-20 in the online supplementary materials summarizes the pooled estimates and forest plots for all the secondary outcomes and adverse events, respectively. Intravenous corticosteroids were associated with lower SOFA scores on day 7 [mean differences (MD), &#x2212;1.37; 95&#x0025; CI = &#x2212;1.91 to &#x2212;0.81] but showed no benefits in mortality related outcomes and the length of hospital or ICU stay in patients with sepsis defined by the Sepsis-3 criteria. However, corticosteroid use was associated with higher risks of hyperglycemia (RR, 1.16; 95&#x0025; CI, 1.06 to 1.27), summarized from 10 RCTs including more than 6,000 patients. The funnel plots (eFigure 21-30 in the online supplementary materials) suggest that the 90-day mortality, ICU mortality, and hyperglycemia suffered from potential reporting bias.</p>
</sec>
<sec id="s3d">
<title>Subgroup analysis</title>
<p>Subgroup analyses suggested that risks of mortality may vary with the durations of corticosteroid treatments: although patients with sepsis receiving corticosteroid treatments for more than 7 days had a borderline increased risk of mortality (RR, 1.10; 95&#x0025; CI, 1.00 to 1.20), the risk remained the same for those with treatment duration less than 7 days (RR, 0.87; 95&#x0025; CI, 0.69 to 1.09) (<xref rid="tbl3" ref-type="table">Table 3</xref>). Overall, there was no association between corticosteroid treatments and 28-day mortality, regardless of the types and dosages of corticosteroids. eFigure 31-41 (see online supplementary materials) displays the forest plots for the subgroup analyses. Importantly, we did not perform the subgroup analysis stratified based on disease severity (septic shock or not) because all included RCTs that reported the 28-day mortality had a mixed study cohort comprising patients with only sepsis and those who had progressed to septic shock (eTable 3 in the online supplementary materials).</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>In this systematic review and meta-analysis of 24 RCTs, we found that intravenous corticosteroids were not associated with lower 28-day mortality in adult patients with sepsis defined by the Sepsis-3 definitions, but were significantly associated with lower SOFA scores on day 7 and increased risks of hyperglycemia.</p>
<p>Based on extensive search in PubMed and Embase, we found 8 systematic reviews and meta-analyses<sup><xref rid="c18" ref-type="bibr">18</xref>-<xref rid="c20" ref-type="bibr">20</xref> <xref rid="c50" ref-type="bibr">50</xref>-<xref rid="c54" ref-type="bibr">54</xref></sup> on the use of corticosteroids in patients with sepsis had been published since 2018. Although all of these reviews included the two largest RCTs, the ADRENAL trial<sup><xref rid="c3" ref-type="bibr">3</xref></sup> and the APROCCHSS trial,<sup><xref rid="c2" ref-type="bibr">2</xref></sup> and included a substantial number of other RCTs, they reported contradictory results. In particular, 4 reviews<sup><xref rid="c18" ref-type="bibr">18</xref> <xref rid="c19" ref-type="bibr">19</xref> <xref rid="c50" ref-type="bibr">50</xref> <xref rid="c51" ref-type="bibr">51</xref></sup> reported that corticosteroids significantly reduced the risk of 28-day mortality, but other four studies<sup><xref rid="c20" ref-type="bibr">20</xref> <xref rid="c52" ref-type="bibr">52</xref>-<xref rid="c54" ref-type="bibr">54</xref></sup> found that intravenous corticosteroids did not lower the risk of either short-term or 28-day mortality. In addition to possible factors such as various outcome definitions or different modeling approaches, we argued that the mixed findings can only be clarified if we first properly standardized the inconsistent definitions for sepsis across previous trials. Our study overcame this limitation by following the Sepsis-3 criteria to define our study cohorts. This precise cohort definition allowed for accurate identification of patients with potential higher mortality rates and reduced the heterogeneity across the included trials, indicated by the I<sup>2</sup> statistics &#x003C;30 in most of our outcomes (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p>
<p>However, our findings should be taken with caution because the disease severity (sepsis vs septic shock or high vs low SOFA score) seemed to modify the association between corticosteroid treatments and the 28-day mortality in the Sepsis-3 cohort. Although our analysis showed that corticosteroids were not associated with reduced 28-day mortality, the post hoc analysis of the ADRENAL trial<sup><xref rid="c16" ref-type="bibr">16</xref></sup> showed that intravenous corticosteroid significantly reduced the 28-day mortality in patients who fulfilled the Sepsis-3 criteria for septic shock (odds ratio, 0.80; 95&#x0025; CI, 0.64 to 0.99, p=0.04). In addition, the APROCCHSS trial,<sup><xref rid="c2" ref-type="bibr">2</xref></sup> which included patients with mean baseline SOFA score of 12&#x2014;much higher than the SOFA score&#x2265;2 required by the Sepsis-3 criteria for sepsis&#x2014;showed that corticosteroids were associated with reduced 90-day mortality (RR, 0.88; 95&#x0025; CI, 0.78 to 0.99, p=0.03). In our study, however, because many of the cohorts included patients from sepsis to septic shock and because not all RCTs reported baseline SOFA scores (<xref rid="tbl1" ref-type="table">Table 1</xref> and eTable 3 in the online supplementary materials), we cannot accurately stratify the study cohorts according to the disease severity. Thus, more research based on well-defined patient inclusion criteria is needed to further clarify whether disease severity may modify the effects of corticosteroids in patients with sepsis.</p>
<p>In addition, our study showed that intravenous corticosteroids were associated with lower SOFA scores on day 7, but the effect did not sustain to improve 28-day survival. This paradoxical phenomenon could be explained by glucocorticoid resistance induced by exogenous corticosteroid, the altered corticosteroid metabolism, and biphasic immunological responses in critical illness. First, the administration of corticosteroid may induce glucocorticoid resistance,<sup><xref rid="c55" ref-type="bibr">55</xref> <xref rid="c56" ref-type="bibr">56</xref></sup> which compromised the efficacy of corticosteroids. In addition, reduced cortisol metabolism increases cortisol levels in patients with critical illness,<sup><xref rid="c57" ref-type="bibr">57</xref></sup> which was associated with higher mortality in patients with severe sepsis.<sup><xref rid="c58" ref-type="bibr">58</xref></sup> Furthermore, biphasic immunological states throughout the clinical course of sepsis,<sup><xref rid="c59" ref-type="bibr">59</xref> <xref rid="c60" ref-type="bibr">60</xref></sup> including an early inflammatory response followed by a chronic immunosuppressed status. This implied that treatment timing may influence the association between corticosteroids and the 28-day mortality because corticosteroid treatments may provide short-term benefits in the early inflammatory phase but have long-term negative impacts in the immunosuppressed state.<sup><xref rid="c59" ref-type="bibr">59</xref></sup> Our subgroup analysis showed that corticosteroid treatment &#x003E; 7 days was associated with higher 28-day mortality also supported this argument based on the biphasic immunological responses. This subgroup analysis, however, included only 3 studies<sup><xref rid="c6" ref-type="bibr">6</xref> <xref rid="c9" ref-type="bibr">9</xref> <xref rid="c43" ref-type="bibr">43</xref></sup> and therefore required further research to confirm the influences of treatment timing on the efficacy of corticosteroids.</p>
<sec id="s4a">
<title>Clinical implications</title>
<p>The recently updated Surviving Sepsis Campaign guidelines<sup><xref rid="c61" ref-type="bibr">61</xref></sup> only recommend the use of intravenous corticosteroid for patients with septic shock who remain hemodynamically unstable after fluid resuscitation and vasopressor support. However, this recommendation was based on the evidence established from studies where participants were defined by the previous definitions.<sup><xref rid="c61" ref-type="bibr">61</xref></sup> The findings of this meta-analysis can, therefore, bridge the clinical gap between guideline recommendations and current evidence to refine clinical use of corticosteroids in patients with sepsis defined by the Sepsis-3 criteria.</p>
</sec>
<sec id="s4b">
<title>Limitations</title>
<p>This study has several limitations. First, although small study effect, reporting bias, and chance may bias our findings, we confirmed that the results in the sensitivity analysis after excluding small studies agreed with the primary analysis, and that the 28-day mortality did not suffer from reporting bias according to the funnel plots. Second, our findings may potentially be biased by the evolving quality of care for sepsis<sup><xref rid="c32" ref-type="bibr">32</xref> <xref rid="c62" ref-type="bibr">62</xref>-<xref rid="c65" ref-type="bibr">65</xref></sup> because we still included trials published back in 1980s and1990s.<sup><xref rid="c39" ref-type="bibr">39</xref> <xref rid="c40" ref-type="bibr">40</xref> <xref rid="c42" ref-type="bibr">42</xref> <xref rid="c45" ref-type="bibr">45</xref></sup> Nevertheless, the sensitivity analysis excluding trials published before 2012 still agreed with the primary analysis. Third, we may underestimate the effects of corticosteroids in some subgroup analysis with fewer available data due to inadequate statistical power (<xref rid="tbl3" ref-type="table">Table 3</xref>). Lastly, we excluded clinical trials without adequate published inclusion details necessary for the Sepsis-3 criteria; therefore, patients fulfilling the Sepsis-3 definitions in these studies may be excluded and therefore were underrepresented in this study.</p>
</sec>
</sec>
<sec id="s5">
<title>Conclusion</title>
<p>This meta-analysis suggested that intravenous corticosteroids compared to standard of care or placebo did not significantly reduce the 28-day mortality and were associated with an increased risk of hyperglycemia in patients with sepsis defined by the Sepsis-3 criteria. Further studies are warranted to understand the roles of disease severity and treatment timing on the efficacy of corticosteroid treatment in this population.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplementary Materials</label>
<media xlink:href="supplements/265100_file04.docx" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All data produced in the present work are contained in the manuscript
</p>
</sec>
<sec id="s6">
<title>Footnotes</title>
</sec>
<ack>
<title>Acknowledgements</title>
<p>None</p>
</ack>
<sec id="s7">
<title>Author contributions</title>
<p>Dr. Wu had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.</p>
<p><italic>Concept and design</italic>: Y. Wu, and S. Papatheodorou.</p>
<p><italic>Acquisition, analysis, or interpretation of data</italic>: All authors.</p>
<p><italic>Drafting of the manuscript</italic>: Y. Wu</p>
<p><italic>Critical revision of the manuscript for important intellectual content</italic>: Y. Wu, C. Lin, R. Hamaya, F. Huang, S. Chen, and S. Papatheodorou.</p>
<p><italic>Statistical analysis:</italic> Y. Wu, and C. Lin</p>
<p><italic>Administrative, technical, or material support:</italic> All authors.</p>
<p><italic>Supervision:</italic> S. Papatheodorou</p>
<p>All authors have read and approved the content for submission.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Competing interests</title>
<p>Yu-Pu Wu, Cheng-Kuan Lin, Fei-Yang Huang, Yung-Shin Chien, Yu-Tien Hsu, Szu-Ta Chen, and Stefania Papatheodorou declared that they had no conflict of interest with respect to the financial interests, activities, relationships, and affiliations. The activity of Rikuta Hamaya was supported by The Nakajima Foundation.</p>
</sec>
<sec id="s9">
<title>Patient consent</title>
<p>Not required.</p>
</sec>
<sec id="s10">
<title>Funding</title>
<p>No funding was used to support this study.</p>
</sec>
<sec id="s11">
<title>Data sharing statement</title>
<p>Extracted data are available by request to the corresponding author <email>hiarpu@gmail.com</email>.</p>
</sec>
<ref-list>
<title>Reference</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Marik</surname> <given-names>PE</given-names></string-name>. <article-title>The role of glucocorticoids as adjunctive treatment for sepsis in the modern era</article-title>. <source>The Lancet Respiratory Medicine</source> <year>2018</year>;<volume>6</volume>(<issue>10</issue>):<fpage>793</fpage>&#x2013;<lpage>800</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Annane</surname> <given-names>D</given-names></string-name>, <string-name><surname>Renault</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brun-Buisson</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Hydrocortisone plus fludrocortisone for adults with septic shock</article-title>. <source>New England Journal of Medicine</source> <year>2018</year>;<volume>378</volume>(<issue>9</issue>):<fpage>809</fpage>&#x2013;<lpage>18</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Venkatesh</surname> <given-names>B</given-names></string-name>, <string-name><surname>Finfer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Adjunctive glucocorticoid therapy in patients with septic shock</article-title>. <source>New England Journal of Medicine</source> <year>2018</year>;<volume>378</volume>(<issue>9</issue>):<fpage>797</fpage>&#x2013;<lpage>808</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Bone</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Balk</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Cerra</surname> <given-names>FB</given-names></string-name>, <etal>et al.</etal> <article-title>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</article-title>. <source>Chest</source> <year>1992</year>;<volume>101</volume>(<issue>6</issue>):<fpage>1644</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1378/chest.101.6.1644</pub-id> [Published Online First: 1992/06/01]</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Cicarelli</surname> <given-names>DD</given-names></string-name>, <string-name><surname>Vieira</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Bense&#x00F1;or</surname> <given-names>FEM.</given-names></string-name> <article-title>Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial</article-title>. <source>Sao Paulo Medical Journal</source> <year>2007</year>;<volume>125</volume>(<issue>4</issue>):<fpage>237</fpage>&#x2013;<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Gordon</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Mason</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Thirunavukkarasu</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial</article-title>. <source>Jama</source> <year>2016</year>;<volume>316</volume>(<issue>5</issue>):<fpage>509</fpage>&#x2013;<lpage>18</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Annane</surname> <given-names>D</given-names></string-name>, <string-name><surname>S&#x00E9;bille</surname> <given-names>V</given-names></string-name>, <string-name><surname>Charpentier</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock</article-title>. <source>Jama</source> <year>2002</year>;<volume>288</volume>(<issue>7</issue>):<fpage>862</fpage>&#x2013;<lpage>71</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Lv</surname> <given-names>Q-q</given-names></string-name>, <string-name><surname>Gu</surname> <given-names>X-h</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Q-h</given-names></string-name>, <etal>et al.</etal> <article-title>Early initiation of low-dose hydrocortisone treatment for septic shock in adults: a randomized clinical trial</article-title>. <source>The American journal of emergency medicine</source> <year>2017</year>;<volume>35</volume>(<issue>12</issue>):<fpage>1810</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Sprung</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Annane</surname> <given-names>D</given-names></string-name>, <string-name><surname>Keh</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Hydrocortisone therapy for patients with septic shock</article-title>. <source>New England Journal of Medicine</source> <year>2008</year>;<volume>358</volume>(<issue>2</issue>):<fpage>111</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Oppert</surname> <given-names>M</given-names></string-name>, <string-name><surname>Schindler</surname> <given-names>R</given-names></string-name>, <string-name><surname>Husung</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock</article-title>. <source>Critical care medicine</source> <year>2005</year>;<volume>33</volume>(<issue>11</issue>):<fpage>2457</fpage>&#x2013;<lpage>64</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Singer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Deutschman</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Seymour</surname> <given-names>CW</given-names></string-name>, <etal>et al.</etal> <article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source>Jama</source> <year>2016</year>;<volume>315</volume>(<issue>8</issue>):<fpage>801</fpage>&#x2013;<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="book"><string-name><surname>Vincent</surname> <given-names>J-L</given-names></string-name>, <string-name><surname>Opal</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Marshall</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <chapter-title>Sepsis definitions: time for change</chapter-title>. <source>Lancet</source> (<publisher-loc>London, England</publisher-loc>) <year>2013</year>;<volume>381</volume>(<issue>9868</issue>):<fpage>774</fpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Esposito</surname> <given-names>S</given-names></string-name>, <string-name><surname>De Simone</surname> <given-names>G</given-names></string-name>, <string-name><surname>Boccia</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches</article-title>. <source>Journal of global antimicrobial resistance</source> <year>2017</year>;<volume>10</volume>:<fpage>204</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Seymour</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>VX</given-names></string-name>, <string-name><surname>Iwashyna</surname> <given-names>TJ</given-names></string-name>, <etal>et al.</etal> <article-title>Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</article-title>. <source>Jama</source> <year>2016</year>;<volume>315</volume>(<issue>8</issue>):<fpage>762</fpage>&#x2013;<lpage>74</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Komorowski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Celi</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Badawi</surname> <given-names>O</given-names></string-name>, <etal>et al.</etal> <article-title>The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care</article-title>. <source>Nature medicine</source> <year>2018</year>;<volume>24</volume>(<issue>11</issue>):<fpage>1716</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Venkatesh</surname> <given-names>B</given-names></string-name>, <string-name><surname>Finfer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion CriteriaA Post Hoc Analysis of the ADRENAL Trial</article-title>. <source>Anesthesiology: The Journal of the American Society of Anesthesiologists</source> <year>2019</year>;<volume>131</volume>(<issue>6</issue>):<fpage>1292</fpage>&#x2013;<lpage>300</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Moher</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liberati</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tetzlaff</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS med</source> <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e1000097</fpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="other"><string-name><surname>Annane</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bellissant</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bollaert</surname> <given-names>PE</given-names></string-name>, <etal>et al.</etal> <source>Corticosteroids for treating sepsis in children and adults. Cochrane Database of Systematic Reviews</source> <year>2019</year>(<issue>12</issue>)</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Fang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tang</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis</article-title>. <source>JAMA internal medicine</source> <year>2019</year>;<volume>179</volume>(<issue>2</issue>):<fpage>213</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Ryg&#x00E5;rd</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Butler</surname> <given-names>E</given-names></string-name>, <string-name><surname>Granholm</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis</article-title>. <source>Intensive care medicine</source> <year>2018</year>;<volume>44</volume>(<issue>7</issue>):<fpage>1003</fpage>&#x2013;<lpage>16</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="other"><string-name><surname>Sterne</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Savovi&#x0107;</surname> <given-names>J</given-names></string-name>, <string-name><surname>Page</surname> <given-names>MJ</given-names></string-name>, <etal>et al.</etal> <article-title>RoB 2: a revised tool for assessing risk of bias in randomised trials</article-title>. <source>bmj</source> <year>2019;366</year></mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Vist</surname> <given-names>GE</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</article-title>. <source>Bmj</source> <year>2008</year>;<volume>336</volume>(<issue>7650</issue>):<fpage>924</fpage>&#x2013;<lpage>26</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Vist</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE guidelines: 4. Rating the quality of evidence&#x2014; study limitations (risk of bias)</article-title>. <source>Journal of clinical epidemiology</source> <year>2011</year>;<volume>64</volume>(<issue>4</issue>):<fpage>407</fpage>&#x2013;<lpage>15</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Kunz</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE guidelines 6. Rating the quality of evidence&#x2014; imprecision</article-title>. <source>Journal of clinical epidemiology</source> <year>2011</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1283</fpage>&#x2013;<lpage>93</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Kunz</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE guidelines: 7. Rating the quality of evidence&#x2014; inconsistency</article-title>. <source>Journal of clinical epidemiology</source> <year>2011</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1294</fpage>&#x2013;<lpage>302</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Kunz</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE guidelines: 8. Rating the quality of evidence&#x2014; indirectness</article-title>. <source>Journal of clinical epidemiology</source> <year>2011</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1303</fpage>&#x2013;<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Montori</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE guidelines: 5. Rating the quality of evidence&#x2014;publication bias</article-title>. <source>Journal of clinical epidemiology</source> <year>2011</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1277</fpage>&#x2013;<lpage>82</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>IntHout</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ioannidis</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Borm</surname> <given-names>GF</given-names></string-name>. <article-title>The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method</article-title>. <source>BMC medical research methodology</source> <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>25</fpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="website"><string-name><surname>Deeks</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Higgins</surname> <given-names>JPT</given-names></string-name>, <string-name><surname>Altman</surname> <given-names>DG</given-names></string-name> (editors). <article-title>Chapter 10: Analysing data and undertaking meta-analyses</article-title>. In: <person-group person-group-type="editor">Higgins JPT, <string-name><surname>Thomas</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chandler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cumpston</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>T</given-names></string-name>, <string-name><surname>Page</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Welch</surname> <given-names>VA</given-names></string-name></person-group> (editors). <source>Cochrane Handbook for Systematic Reviews of Interventions version 6.0</source> (updated July 2019). Cochrane, <year>2019</year>. Available from <ext-link ext-link-type="uri" xlink:href="http://www.training.cochrane.org/handbook">www.training.cochrane.org/handbook</ext-link>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Harbord</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Egger</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sterne</surname> <given-names>JA</given-names></string-name>. <article-title>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</article-title>. <source>Statistics in medicine</source> <year>2006</year>;<volume>25</volume>(<issue>20</issue>):<fpage>3443</fpage>&#x2013;<lpage>57</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Borenstein</surname> <given-names>M</given-names></string-name>, <string-name><surname>Higgins</surname> <given-names>JP</given-names></string-name>. <article-title>Meta-analysis and subgroups</article-title>. <source>Prevention science</source> <year>2013</year>;<volume>14</volume>(<issue>2</issue>):<fpage>134</fpage>&#x2013;<lpage>43</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Dellinger</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Levy</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Rhodes</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012</article-title>. <source>Intensive care medicine</source> <year>2013</year>;<volume>39</volume>(<issue>2</issue>):<fpage>165</fpage>&#x2013;<lpage>228</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="other"><string-name><surname>Harrer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cuijpers</surname> <given-names>P</given-names></string-name>, <string-name><surname>Furukawa</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <source>Doing meta-analysis in R: A hands-on guide. PROTECT Lab Erlangen</source> <year>2019</year></mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Sabry</surname> <given-names>NA</given-names></string-name>, <string-name><given-names>Omar EE-D.</given-names> <surname>Corticosteroids</surname></string-name> and <string-name><given-names>ICU course of community acquired pneumonia in Egyptian</given-names> <surname>settings</surname></string-name>. <source>Pharmacology &#x0026; Pharmacy</source> <year>2011</year>;<volume>2</volume>(<issue>02</issue>):<fpage>73</fpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Fern&#x00E1;ndez-Serrano</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dorca</surname> <given-names>J</given-names></string-name>, <string-name><surname>Garcia-Vidal</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial</article-title>. <source>Critical Care</source> <year>2011</year>;<volume>15</volume>(<issue>2</issue>):<fpage>R96</fpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Confalonieri</surname> <given-names>M</given-names></string-name>, <string-name><surname>Urbino</surname> <given-names>R</given-names></string-name>, <string-name><surname>Potena</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study</article-title>. <source>American journal of respiratory and critical care medicine</source> <year>2005</year>;<volume>171</volume>(<issue>3</issue>):<fpage>242</fpage>&#x2013;<lpage>48</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Tongyoo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Permpikul</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mongkolpun</surname> <given-names>W</given-names></string-name>, <etal>et al.</etal> <article-title>Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial</article-title>. <source>Critical Care</source> <year>2016</year>;<volume>20</volume>(<issue>1</issue>):<fpage>329</fpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Arabi</surname> <given-names>YM</given-names></string-name>, <string-name><surname>Aljumah</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dabbagh</surname> <given-names>O</given-names></string-name>, <etal>et al.</etal> <article-title>Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial</article-title>. <source>Cmaj</source> <year>2010</year>;<volume>182</volume>(<issue>18</issue>):<fpage>1971</fpage>&#x2013;<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Bollaert</surname> <given-names>P-E</given-names></string-name>, <string-name><surname>Charpentier</surname> <given-names>C</given-names></string-name>, <string-name><surname>Levy</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title>Reversal of late septic shock with supraphysiologic doses of hydrocortisone</article-title>. <source>Critical care medicine</source> <year>1998</year>;<volume>26</volume>(<issue>4</issue>):<fpage>645</fpage>&#x2013;<lpage>50</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Briegel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Forst</surname> <given-names>H</given-names></string-name>, <string-name><surname>Haller</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study</article-title>. <source>Critical care medicine</source> <year>1999</year>;<volume>27</volume>(<issue>4</issue>):<fpage>723</fpage>&#x2013;<lpage>32</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Hu</surname> <given-names>B</given-names></string-name>, <string-name><surname>Li</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock</article-title>. <source>Zhongguo wei zhong bing ji jiu yi xue= Chinese critical care medicine= Zhongguo weizhongbing jijiuyixue</source> <year>2009</year>;<volume>21</volume>(<issue>9</issue>):<fpage>529</fpage>&#x2013;<lpage>31</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Sprung</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Caralis</surname> <given-names>PV</given-names></string-name>, <string-name><surname>Marcial</surname> <given-names>EH</given-names></string-name>, <etal>et al.</etal> <article-title>The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study</article-title>. <source>New England Journal of Medicine</source> <year>1984</year>;<volume>311</volume>(<issue>18</issue>):<fpage>1137</fpage>&#x2013;<lpage>43</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Gordon</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Mason</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Perkins</surname> <given-names>GD</given-names></string-name>, <etal>et al.</etal> <article-title>The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial</article-title>. <source>Critical care medicine</source> <year>2014</year>;<volume>42</volume>(<issue>6</issue>):<fpage>1325</fpage>&#x2013;<lpage>33</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Gang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chengdong</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Value of glucocorticoid steroids in the treatment of patients with severe community-acquired pneumonia complicated with septic shock</article-title>. <source>Chinese Critical Care Medicine</source> <year>2016</year>;<volume>28</volume>(<issue>9</issue>):<fpage>780</fpage>&#x2013;<lpage>84</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Chawla</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kupfer</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Goldman</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal> <article-title>Hydrocortisone reverses refractory septic shock</article-title>. <source>Critical Care Medicine</source> <year>1999</year>;<volume>27</volume>(<issue>1</issue>):<fpage>33A</fpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Bennett</surname> <given-names>I</given-names></string-name>, <string-name><surname>Finland</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hamburger</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>The effectiveness of hydrocortisone in the management of severe infections</article-title>. <source>Jama</source> <year>1963</year>;<volume>183</volume>(<issue>6</issue>):<fpage>462</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Talebi Doluee</surname> <given-names>M</given-names></string-name>, <string-name><surname>Salehi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mahmoudi Gharaee</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>The effect of physiologic dose of intravenous hydrocortisone in patients with refractory septic shock: a randomized control trial</article-title>. <source>Journal of Emergency Practice and Trauma</source> <year>2018</year>;<volume>4</volume>(<issue>1</issue>):<fpage>29</fpage>&#x2013;<lpage>33</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Fan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ronaghi</surname> <given-names>R</given-names></string-name>, <string-name><surname>Rees</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>THE EFFECT OF USING VITAMIN C, HYDROCORTISONE, AND THIAMINE TRIPLE THERAPY IN THE TREATMENT OF SEPTIC SHOCK</article-title>. <source>Chest</source> <year>2019</year>;<volume>156</volume>(<issue>4</issue>):<fpage>A944</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chest.2019.08.874</pub-id></mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Wani</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Mufti</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Jan</surname> <given-names>RA</given-names></string-name>, <etal>et al.</etal> <article-title>Combination of vitamin C, thiamine and hydrocortisone added to standard treatment in the management of sepsis: results from an open label randomised controlled clinical trial and a review of the literature</article-title>. <source>Infectious Diseases</source> <year>2020</year>;<volume>52</volume>(<issue>4</issue>):<fpage>271</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="other"><string-name><surname>Lian</surname> <given-names>X-J</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>D-Z</given-names></string-name>, <string-name><surname>Cao</surname> <given-names>Y-S</given-names></string-name>, <etal>et al.</etal> <article-title>Reevaluating the Role of Corticosteroids in Septic Shock: An Updated Meta-Analysis of Randomized Controlled Trials</article-title>. <source>BioMed research international</source> <year>2019;2019</year></mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Ni</surname> <given-names>Y-N</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y-M</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y-W</given-names></string-name>, <etal>et al.</etal> <article-title>Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis</article-title>. <source>The American journal of emergency medicine</source> <year>2019</year>;<volume>37</volume>(<issue>9</issue>):<fpage>1657</fpage>&#x2013;<lpage>64</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Rochwerg</surname> <given-names>B</given-names></string-name>, <string-name><surname>Oczkowski</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Siemieniuk</surname> <given-names>RA</given-names></string-name>, <etal>et al.</etal> <article-title>Corticosteroids in sepsis: an updated systematic review and meta-analysis</article-title>. <source>Critical care medicine</source> <year>2018</year>;<volume>46</volume>(<issue>9</issue>):<fpage>1411</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname> <given-names>X</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yao</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of adjunctive corticosteroids on clinical outcomes in adult patients with septic shock-a meta-analysis of randomized controlled trials and trial sequential analysis</article-title>. <source>Journal of critical care</source> <year>2018</year>;<volume>48</volume>:<fpage>296</fpage>&#x2013;<lpage>306</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Wen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>Q</given-names></string-name>, <etal>et al.</etal> <article-title>The effectiveness and safety of corticosteroids therapy in adult critical Ill patients with septic shock: a meta-analysis of randomized controlled trials</article-title>. <source>Shock</source> <year>2019</year>;<volume>52</volume>(<issue>2</issue>):<fpage>198</fpage>&#x2013;<lpage>207</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Ledderose</surname> <given-names>C</given-names></string-name>, <string-name><surname>M&#x00F6;hnle</surname> <given-names>P</given-names></string-name>, <string-name><surname>Limbeck</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Corticosteroid resistance in sepsis is influenced by microRNA-124&#x2013;induced downregulation of glucocorticoid receptor-&#x03B1;</article-title>. <source>Critical care medicine</source> <year>2012</year>;<volume>40</volume>(<issue>10</issue>):<fpage>2745</fpage>&#x2013;<lpage>53</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Marik</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Pastores</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Annane</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine</article-title>. <source>Critical care medicine</source> <year>2008</year>;<volume>36</volume>(<issue>6</issue>):<fpage>1937</fpage>&#x2013;<lpage>49</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Boonen</surname> <given-names>E</given-names></string-name>, <string-name><surname>Vervenne</surname> <given-names>H</given-names></string-name>, <string-name><surname>Meersseman</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title>Reduced cortisol metabolism during critical illness</article-title>. <source>New England Journal of Medicine</source> <year>2013</year>;<volume>368</volume>(<issue>16</issue>):<fpage>1477</fpage>&#x2013;<lpage>88</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Sam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Corbridge</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Mokhlesi</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title>Cortisol levels and mortality in severe sepsis</article-title>. <source>Clinical endocrinology</source> <year>2004</year>;<volume>60</volume>(<issue>1</issue>):<fpage>29</fpage>&#x2013;<lpage>35</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Hotchkiss</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Sherwood</surname> <given-names>ER</given-names></string-name>. <article-title>Getting sepsis therapy right</article-title>. <source>Science</source> <year>2015</year>;<volume>347</volume>(<issue>6227</issue>):<fpage>1201</fpage>&#x2013;<lpage>02</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Hotchkiss</surname> <given-names>RS</given-names></string-name>, <string-name><surname>Moldawer</surname> <given-names>LL</given-names></string-name>, <string-name><surname>Opal</surname> <given-names>SM</given-names></string-name>, <etal>et al.</etal> <article-title>Sepsis and septic shock</article-title>. <source>Nature reviews Disease primers</source> <year>2016</year>;<volume>2</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Rhodes</surname> <given-names>A</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Alhazzani</surname> <given-names>W</given-names></string-name>, <etal>et al.</etal> <article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016</article-title>. <source>Intensive care medicine</source> <year>2017</year>;<volume>43</volume>(<issue>3</issue>):<fpage>304</fpage>&#x2013;<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><collab>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis</collab>. <source>Crit Care Med</source> <year>1992</year>;<volume>20</volume>(<issue>6</issue>):<fpage>864</fpage>-<lpage>74</lpage>. [Published Online First: 1992/06/01]</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Levy</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Fink</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Marshall</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <article-title>2001 sccm/esicm/accp/ats/sis international sepsis definitions conference</article-title>. <source>Intensive care medicine</source> <year>2003</year>;<volume>29</volume>(<issue>4</issue>):<fpage>530</fpage>&#x2013;<lpage>38</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Dellinger</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Carlet</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Masur</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock</article-title>. <source>Intensive care medicine</source> <year>2004</year>;<volume>30</volume>(<issue>4</issue>):<fpage>536</fpage>&#x2013;<lpage>55</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Dellinger</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Levy</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Carlet</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</article-title>. <source>Intensive care medicine</source> <year>2008</year>;<volume>34</volume>(<issue>1</issue>):<fpage>17</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>